Global Neuro-Oncology

Annias Immunotherapeutics, formerly known as Global Neuro-Oncology, is a clinical-stage biotechnology company focused on developing immunotherapies for brain tumors. The company's lead candidate, AN-1001 (formerly GNO-101), is a multi-antigen peptide vaccine designed to target glioblastoma multiforme (GBM). The vaccine specifically targets cytomegalovirus (CMV) antigens, which are frequently expressed in GBM cells but not in healthy brain tissue. By stimulating a targeted T-cell response, Annias aims to provide a more effective and less toxic treatment option for patients with aggressive gliomas. The company's technology is based on research licensed from Duke University and is currently being evaluated in Phase 2 clinical trials.